BioPharmaPT
← All reports

AbbVie Inc. — Aquipta EMA EPAR public assessment report (EMEA/H/C/005871, 2023)

AbbVie Inc. · 2023 · EMA EPAR public assessment report · company profile →

Report summary

The European Medicines Agency (EMA) granted marketing authorization for AbbVie's Aquipta (atogepant) for adult migraine prophylaxis. The assessment confirmed atogepant's quality, non-clinical safety (non-genotoxic, non-carcinogenic), and pharmacokinetic profile, including dose proportionality and drug interactions. Clinical trials demonstrated significant reductions in monthly migraine days, headache days, and acute medication use in both episodic and chronic migraine, with an early and sustained effect. Common adverse events included nausea, constipation, and fatigue. While generally favorable, continued monitoring for hepatic safety is recommended due to post-marketing reports of liver injury.

Key findings — cited to the page

Atogepant pKa12.2 Aquipta · p.12
Atogepant partition coefficient (LogP)2.4 Aquipta · p.12
CHMP positive opinion for marketing authorisation22 June 2023 Aquipta · p.9
Atogepant tablet strength60 mg Aquipta · p.11
Indication for Aquiptaprophylaxis of migraine in adults who have at least 4 migraine days per month Aquipta · p.7
Atogepant molecular weight (monohydrate form)621.544 g/molAquipta · p.11
Duration of migraine attacks if untreated or unsuccessfully treated4 to 72 hours · p.9
Chronic migraine definition: headache days per month15 or more days per month · p.10
Chronic migraine definition: migraine headache days per monthat least 8 days per month · p.10
Atogepant tablet strength10 mg Aquipta · p.11
Subjects received atogepant in PCS1837 · p.95
Atogepant pKa210.2 Aquipta · p.12

Source: AbbVie Inc. · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Neurology library →

AbbVie Inc. — Aquipta EMA EPAR public assessment report (EMEA/H/C/005871, 2023) — Summary & Key Findings | BioPharmaPT